Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Open-label, Multicenter Study, IBI310 in Combination With IBI308 and IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery

Next Previous
Trial Profile

A Phase 3, Open-label, Multicenter Study, IBI310 in Combination With IBI308 and IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Sintilimab (Primary) ; Interferon alpha-2b
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Innovent Biologics

Most Recent Events

  • 07 Mar 2023 Status changed from active, no longer recruiting to discontinued.
  • 03 Oct 2022 Planned End Date changed from 1 Apr 2025 to 1 Jun 2023.
  • 03 Oct 2022 Planned primary completion date changed from 18 Apr 2024 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top